메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색
질문

논문 기본 정보

자료유형
학술저널
저자정보
김병수 (경북대학교)
저널정보
대한생물치료정신의학회 생물치료정신의학 생물치료정신의학 제26권 제2호(통권 제58호)
발행연도
2020.6
수록면
79 - 87 (9page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색
질문

초록· 키워드

오류제보하기
Major depressive disorder is a highly prevalent psychiatric condition that causes serious health concern and psychosocial consequences. Nevertheless, about one third of the patients with major depressive disorder have treatmentresistant depression (i.e., a failure to respond to two or more antidepressant drugs). In addition, it takes at least two weeks to several months before the antidepressants have an effect. In the field of emergency psychiatry, this time lag has always been a serious obstacle in the treatment of suicidal patients. Since 2000, the ketamine has emerged as a novel therapeutic agent for major depressive disorder and suicidality with rapid onset and robust response rates. In 2019, the U.S. Food and Drug Administration (U.S. FDA) approved the S-enantiomer of ketamine, esketamine as a drug for treatment-resistant depression. However, the U.S. FDA approved it with a Risk Evaluation and Mitigation Strategy (REMS) to mitigate the risk of serious adverse effects resulting from sedation, dissociation, cardiovascular instability, and potential abuse. Although we still do not have enough experience about the efficacy and safety of this new medication, the interests of clinicians and patients are rapidly growing. In this narrative review, the pharmacological characteristics, the mechanism of action, the psychiatric effects and side effects, and a consensus statement on the use of ketamine were provided.

목차

서론
본론
결론
참고문헌

참고문헌 (47)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

이 논문과 함께 이용한 논문

최근 본 자료

전체보기

댓글(0)

0

UCI(KEPA) : I410-ECN-0101-2020-512-000659415